Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

Kazuhiko Kakihana, Yuki Fujioka, Wataru Suda, Yuho Najima, Go Kuwata, Satoshi Sasajima, Iyo Mimura, Hidetoshi Morita, Daisuke Sugiyama, Hiroyoshi Nishikawa, Masahira Hattori, Yutaro Hino, Shuntaro Ikegawa, Keita Yamamoto, Takashi Toya, Noriko Doki, Koichi Koizumi, Kenya Honda, Kazuteru Ohashi

    Research output: Contribution to journalReview article

    87 Citations (Scopus)

    Abstract

    Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.

    Original languageEnglish
    Pages (from-to)2083-2088
    Number of pages6
    JournalBlood
    Volume128
    Issue number16
    DOIs
    Publication statusPublished - 2016 Oct 20

    Fingerprint

    Transplantation (surgical)
    Graft vs Host Disease
    Grafts
    Stem cells
    Steroids
    Stem Cell Transplantation
    T-cells
    Microbiota
    Fecal Microbiota Transplantation
    Regulatory T-Lymphocytes
    Safety

    ASJC Scopus subject areas

    • Immunology
    • Biochemistry
    • Hematology
    • Cell Biology

    Cite this

    Kakihana, K., Fujioka, Y., Suda, W., Najima, Y., Kuwata, G., Sasajima, S., ... Ohashi, K. (2016). Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood, 128(16), 2083-2088. https://doi.org/10.1182/blood-2016-05-717652

    Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. / Kakihana, Kazuhiko; Fujioka, Yuki; Suda, Wataru; Najima, Yuho; Kuwata, Go; Sasajima, Satoshi; Mimura, Iyo; Morita, Hidetoshi; Sugiyama, Daisuke; Nishikawa, Hiroyoshi; Hattori, Masahira; Hino, Yutaro; Ikegawa, Shuntaro; Yamamoto, Keita; Toya, Takashi; Doki, Noriko; Koizumi, Koichi; Honda, Kenya; Ohashi, Kazuteru.

    In: Blood, Vol. 128, No. 16, 20.10.2016, p. 2083-2088.

    Research output: Contribution to journalReview article

    Kakihana, K, Fujioka, Y, Suda, W, Najima, Y, Kuwata, G, Sasajima, S, Mimura, I, Morita, H, Sugiyama, D, Nishikawa, H, Hattori, M, Hino, Y, Ikegawa, S, Yamamoto, K, Toya, T, Doki, N, Koizumi, K, Honda, K & Ohashi, K 2016, 'Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut', Blood, vol. 128, no. 16, pp. 2083-2088. https://doi.org/10.1182/blood-2016-05-717652
    Kakihana, Kazuhiko ; Fujioka, Yuki ; Suda, Wataru ; Najima, Yuho ; Kuwata, Go ; Sasajima, Satoshi ; Mimura, Iyo ; Morita, Hidetoshi ; Sugiyama, Daisuke ; Nishikawa, Hiroyoshi ; Hattori, Masahira ; Hino, Yutaro ; Ikegawa, Shuntaro ; Yamamoto, Keita ; Toya, Takashi ; Doki, Noriko ; Koizumi, Koichi ; Honda, Kenya ; Ohashi, Kazuteru. / Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. In: Blood. 2016 ; Vol. 128, No. 16. pp. 2083-2088.
    @article{054aa78b5c214992b1da2e33373914cc,
    title = "Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut",
    abstract = "Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.",
    author = "Kazuhiko Kakihana and Yuki Fujioka and Wataru Suda and Yuho Najima and Go Kuwata and Satoshi Sasajima and Iyo Mimura and Hidetoshi Morita and Daisuke Sugiyama and Hiroyoshi Nishikawa and Masahira Hattori and Yutaro Hino and Shuntaro Ikegawa and Keita Yamamoto and Takashi Toya and Noriko Doki and Koichi Koizumi and Kenya Honda and Kazuteru Ohashi",
    year = "2016",
    month = "10",
    day = "20",
    doi = "10.1182/blood-2016-05-717652",
    language = "English",
    volume = "128",
    pages = "2083--2088",
    journal = "Blood",
    issn = "0006-4971",
    publisher = "American Society of Hematology",
    number = "16",

    }

    TY - JOUR

    T1 - Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut

    AU - Kakihana, Kazuhiko

    AU - Fujioka, Yuki

    AU - Suda, Wataru

    AU - Najima, Yuho

    AU - Kuwata, Go

    AU - Sasajima, Satoshi

    AU - Mimura, Iyo

    AU - Morita, Hidetoshi

    AU - Sugiyama, Daisuke

    AU - Nishikawa, Hiroyoshi

    AU - Hattori, Masahira

    AU - Hino, Yutaro

    AU - Ikegawa, Shuntaro

    AU - Yamamoto, Keita

    AU - Toya, Takashi

    AU - Doki, Noriko

    AU - Koizumi, Koichi

    AU - Honda, Kenya

    AU - Ohashi, Kazuteru

    PY - 2016/10/20

    Y1 - 2016/10/20

    N2 - Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.

    AB - Increasing evidence indicates that the gut microbiota is closely associated with ACute graft-versus-host disease (aGVHD) in stem cell transplantation (SCT). Fecal microbiota transplantation (FMT) could represent an alternative treatment option for aGVHD. However, FMT for SCT patients carries a potential risk of infection by infused microbiota because of the severely immuno suppressed status. We there for econducte dapilot study to evaluate the safety of FMT in SCT. A total of 4 patients with steroid-resistant (n 53) or steroid-dependent gut aGVHD (n 51) received FMT. No severe adverse events attributed to FMT were observed. All patients responded to FMT, with 3 complete responses and 1 partial response. Temporal dynamics of microbiota seemed to be linked to the gut condition of patients and peripheral effector regulatory T cells also increased during response to FMT. FMT was safely performed in our patients and might offer a novel therapeutic option for aGVHD.

    UR - http://www.scopus.com/inward/record.url?scp=84992074418&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=84992074418&partnerID=8YFLogxK

    U2 - 10.1182/blood-2016-05-717652

    DO - 10.1182/blood-2016-05-717652

    M3 - Review article

    VL - 128

    SP - 2083

    EP - 2088

    JO - Blood

    JF - Blood

    SN - 0006-4971

    IS - 16

    ER -